Animal Tumor Procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis

• References

• 1 Rickies FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983; 62: 14-31
• 2 Curatolo L, Colucci M, Cambini AL, Poggi A, Morasca L, Donati MB, Semeraro N. Evidence that cells from experimental tumors can activate coagulation factor X. Br J Cancer 1979; 40: 228-233
• 3 Delaini F, Colucci M, DeBellis VG, Locati D, Poggi A, Semeraro N, Donati MB. Cancer cell procoagulant: A novel vitamin K-dependent activity. Thromb Res 1981; 24: 263-266
• 4 Pezzi L, Gerna M, Roncaglioni MC, Vermeer C, Donati MB. Increased susceptibility to the anticoagulant effect of warfarin in mice bearing the Lewis Lung Carcinoma. Role of vitamin K deficiency. Biochem Pharmacol 1986; 35: 3239-3242
• 5 Falanga A, Bolognese Dalessandro AP, Casali B, Roncaglioni MC, Donati MB. Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics. Int J Cancer 1987; 39: 774-777
• 6 Hilgard P, Schulte H, Wetzig G, Schmitt G, Schmidt CG. Oral anticoagulation in the treatment of a spontaneously metastasizing murine tumor (3LL). Br J Cancer 1977; 35: 78-85
• 7 Hilgard P. Experimental vitamin K-deficiency and spontaneous metas-tases. Br J Cancer 1977; 35: 891-892
• 8 Hilgard P, Maat B. Mechanism of lung tumor colony reduction caused by coumarin anticoagulation. Eur J Cancer 1979; 15: 183-187
• 9 Hilgard P, Whur P. Factor X-activating activity from Lewis lung carcinoma. Br J Cancer 1980; 41: 642-643
• 10 Kadish JL, Wenc KM, Dvorak HF. Tissue factor activity of normal and neoplastic cells: Quantitation and species specificity. JNCI 1983; 70: 551-557
• 11 Maat B. Selective macrophage inhibition abolishes warfarin-induced reduction of m eta stases. Br T Cancer 1980; 41: 313-316
• 12 Poggi A, Mussoni L, Kornblihtt L, Ballabio E, DeGaetano G, Donati MB. Warfarin enantiomers, antiroagulation, and experimental tumor metastasis. Lancet 1978; 1: 163-164
• 13 Poggi A, Colucci M, Delaini F, Semeraro N, Donati MB. Reduced procoagulant activity of Lewis lung carcinoma cells from mice treated with warfarin. Eur J Cancer 1980; 16: 1641-1642
• 14 Roncaglioni MC, Bolognese Dalessandro AP, Casali B, Vermeer C, Donati MB. Gamma glutamyl carboxylase activity in experimental tumor tissues: A biochemical basis for vitamin K dependence of cancer procoagulant. Haemostasis 1986; 16: 295-299
• 15 Cavanaugh PG, Sloane BF, Bajkowski AS, Taylor JD, Honn KV. Purification and characterization of platelet aggregating activity from tumor cells: Copurification with procoagulant activity. Thromb Res 1985; 37: 309-326
• 16 Gilbert LC, Gordon SG. Relationship between cellular procoagulant activity and metastatic capacity of B16 mouse melanoma variants. Cancer Res 1983; 43: 536-540
• 17 Gordon SG, Gilbert LC, Lewis B. Analysis of procoagulant activity of intact cells from tissue culture. Thromb Res 1982; 26: 379-387
• 18 Peters LJ, Hewitt HB. The influence of fibrin formation on the transplantability of murine tumor cells: Implications for the mechanism of the Revesz effect. Br J Cancer 1974; 29: 279-291
• 19 Pearlstein EP, Ambrogio C, Gasic GJ, Karpatkin S. Inhibition of platelet aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with specific thrombin inhibitor, dansyl arginine N–[3–ethyl–1,5 pentadiyl] amide. Cancer Res 1981; 41: 4533-4539
• 20 Chmielewska J, Poggi A, Mussoni L, Donati MB, Garattini S. Blood coagulation changes in JW sarcoma, a new metastasizing tumour in mice. Eur J Cancer 1980; 16: 1399-1407
• 21 Colucci M, Giavazzi R, Alessandri G, Semeraro N, Mantovani A, Donati MB. Procoagulant activity of sarcoma sublines with different metastatic potential. Blood 1985; 57: 733-735
• 22 Lorenzet R, Bottazzi B, Locati D, Colucci M, Mantovani A, Semeraro N, Donati MB. Failure of warfarin to affect the tissue factor activity and the metastatic potential of murine fibrosarcoma cells. Eur J Cancer Clin Oncol 1985; 21: 263-265
• 23 Dvorak HF, Quay SC, Orenstein NS, Dvorak AM, Hahn P, Bitzer AM, Carvalho AC. Tumor shedding and coagulation. Science 1981; 212: 923-924
• 24 Dvorak HF, Van De Water L, Bitzer AM, Dvorak AM, Anderson D, Han VS, Bach R, Davis GL, DeWolf W, Carvalho AC A. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 1983; 43: 4334-4342
• 25 Laki K, Tyler HM, Yancey ST. Clot forming and clot stabilizing enzymes from the mouse tumor YPC–1. Biochem Biophys Res Commun 1966; 24: 776-781
• 26 Peterson HI, Appelgren KL, Rudenstam CM, Lewis DH. Studies on the circulation of experimental tumours. I. Effect of induced fibrinolysis and antifibrinolysis on capillary blood flow and the capillary transport function of two experimental tumours in the mouse. Eur J Cancer 1969 5. 91-97
• 27 Lando PA, Biazak CE, Edgington TS. Amidolytic assay for procoagulant activity of lymphoid and tumor cells. J Immunol Meth 1986; 89: 131-139
• 28 Badenoch-Jones P, Ramshaw IA. Characterization of rat tumour cell hybrids: Procoagulant and fibrinolytic activities. Aust J Exp Biol Med Sci 1985; 63: 91-98
• 29 Mussoni L, Bertoni MP, Curatolo L, Poggi A, Donati MB. In vitro interaction of J5222 and BNML leukemia cells with fibrin. A preliminary report. Leuk Res 1977 1. 181-183
• 30 Inoue Y, Geczy CL, Nelson DS, Nelson M. Lymphokine-like products of tumour cells. Immunology 1981; 48: 713-722
• 31 Kohga S. Thromboplastic and fibrinolytic activities of ascites tumor cells of rats, with reference to their role in metastasis formation. Gann 1978; 69: 461-470
• 32 Peterson HI, Zettergren L. Thromboplastic and fibrinolytic properties of three transplantable rat tumours. Acta Chir Scand 1970; 136: 365-368
• 33 Dvorak HF, Orenstein NS, Carvalho AC, Churchill WH, Dvorak AM, Galli SJ, Feder J, Bitzer AM, Rypysc J, Giovinco P. Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-severe ted products. J Immunol 1979; 122: 166-174
• 34 Cliffton EE, Grossi CE. Effect of human plasmin on the toxic effects and growth of blood-borne mctastases of the Brown-Pearce carcinoma and the V2 carcinoma of the rabbit. Cancer 1936; 9: 1147-1152
• 35 Lawrence EA, Bowman DE, Moore DB, Bernstein GI. A thromboplastic property of neoplasms. Surg Forum 1952; 3: 694-698
• 36 Gordon SG, Franks JJ, Lewis B. Cancer Procoagulant A: A factor X activating procoagulant from malignant tissue. Thromb Res 1975; 6: 127-137
• 37 Gordon SG, Cross BA. A factor X-activating cysteine protease from malignant tissue. J Clin Invest 1981; 67: 1665-1671
• 38 Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant A: A cysteine proteinase from malignant tissue. Biochemistry 1985; 24: 5558-5567
• 39 Lando PA, Edgington TS. An innate host response to the neoplastic cell: Syngeneic rat tumor cells can elicit a rapid “de novo” lymphoid procoagulant response. J Immunol 1985; 135: 3587-3595
• 40 Peterson HI. Experimental studies on fibrinolysis in growth and spread of tumour. Acta Chir Scand 1968
• 41 VanDeWater L, Tracy PB, Aronson D, Mann KG, Dvorak HF. Tumor cell generation of thrombin via functional prothrombinase assembly. Cancer Res 1985; 45: 5521-5525
• 42 Carr JM, Dvorak AM, Dvorak HF. Circulating membrane vesicles in leukemic blood. Cancer Res 1985; 45: 5944-5951
• 43 Donati MB, Bini A, Colucci M, Conforti MG, Delaini F, Locati D, Lorenzet R, Semeraro N. The V2 carcinoma of the rabbit as a model for tumor invasion: 4. Procoagulant and fibrinolytic activities. In: Tumor Progression and Markers Kugler; Amsterdam: 1982: 51-57
• 44 Fasco MJ, Wilson AC, Lincoln D, Gierthy J. Evidence for a warfarin-sensitive serum factor that participates in factor X activation by Lewis lung tumor cells. Int J Cancer 1987; 39: 631-637
• 45 Colucci M, Delainie F, De Beilis Vitti G, Locati D, Poggi A, Semeraro N, Donati MB. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. Biochem Pharmacol 1983 32. 1689-1691
• 46 Kohga S, Tanaka K. Role of tumor thromboplastin in the mode of distribution of metastatic foci in the lung. Gann 1979; 70: 615-619
• 47 Kodama Y, Tanaka K. Thromboplastic and fibrinolytic activities of V2 and V7 carcinomas of rabbit, with special reference to fibrin deposition and thrombus formation in tumors. Acta Pathol Jpn 1978; 28: 279-286
• 48 Colucci M, Curatolo L, Donati MB, Semeraro N. Cancer cell procoagulant activity: Evaluation by amidolytic assay. Thromb Res 1980; 18: 589-595
• 49 Quick AJ. On various properties of thromboplastin (aqueous tissue extracts). Am J Physiol 1936; 114: 282-296
• 50 Janson TL, Stormorken H, Prydz H. Species specificity of tissue thromboplastin. Haemostasis 1984; 14: 440-444